Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. He maintained his buy rating on the stock.
Several analysts are bullish about Vir’s prospects. But Wainwright’s Trucchio is the most optimistic by far about the biotech stock. What’s behind his enthusiasm?
Image source: Getty Images.